Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

The changing epidemiology of invasive pneumococcal disease

We investigated trends in invasive pneumococcal disease (IPD) in Western Australia (WA).

Research

Vaccinating young adults against HPV: the importance of understanding health decision-making and behaviour

Vaccination of young teenage females against human papillomavirus (HPV) with a newly licenced quadrivalent vaccine designed to prevent cervical cancer and...

News & Events

Wesfarmers tops 2019 GivingLarge Report

The major funder of the Wesfarmers Centre of Vaccines and Infectious Diseases based at The Kids Research Institute Australia has been recognised as Australia’s most generous giver.

News & Events

Babies at risk due to delayed vaccinations

As many as a quarter of Australian babies aren’t getting vaccinated on time, leaving them at risk of developing life-threatening illnesses such as whooping cough when they are most vulnerable.

News & Events

New meningococcal strains bring increased risk in WA

A new study has confirmed the changing pattern of meningococcal disease in Western Australia.

News & Events

The Kids Research Institute Australia leads WA arm of Australia’s first needle-free COVID-19 vaccine study

Enrolments for Australia’s first needle-free, gene-based COVID-19 vaccine study – to be led in WA by The Kids Research Institute Australia – are open.

Research

Influenza

Influenza (commonly known as the flu) is caused by a highly contagious virus spread mainly through coughing and sneezing. An annual flu vaccination is the most effective way to prevent flu outbreaks.

Research

Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response

SARS-CoV-2 nucleocapsid (N) protein antibodies can be used to identify the serological response to natural infection in those who have previously received a COVID-19 spike-based vaccine. Anti-N antibody responses can also be induced by inactivated whole SARS-CoV-2 virus vaccines, such as CoronaVac. We aimed to characterise antibody responses to the N protein following COVID-19 and following vaccination with CoronaVac.

Research

Validity of using a semi-automated screening tool in a systematic review assessing non-specific effects of respiratory vaccines

The abstract screening process of systematic reviews can take thousands of hours by two researchers. We aim to determine the reliability and validity of Research Screener, a semi-automated abstract screening tool within a systematic review on non-specific and broader effects of respiratory vaccines on acute lower respiratory infection hospitalisations and antimicrobial prescribing patterns in young children.

Research

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.